Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia

Exclusion Criteria

• •ECOG 0-2 performance status
• •Biochemical values within the following range
• •Serum creatinine \<2x upper limit of normal
• •Total bilirubin \<1.5x upper limit of normal
• •AST and ALT \<2x upper limit of normal
• •Recovery from non-hematologic toxicity from prior chemotherapy
• •Able and willing to provide informed consent
• •Allergy to tetracycline or minocycline
• •Uncontrolled intercurrent illness such as uncontrolled diabetes or active uncontrolled infection
• •Active systemic bacterial, fungal, or viral infection
• •Concomitant use of linezolid or chloramphenicol that are known to inhibit mitochondrial protein synthesis
• •Pregnant or breast feeding
• •Known active CNS involvement with AML
• •Neurologic symptoms related to uncontrolled illnesses or unexplained causes
• •Psychiatric illness that would limit compliance with study
• •Receiving systemic chemotherapy other than hydroxyurea to control circulating blast counts. Concomitant hydroxyurea is permitted, but only in the first cycle of therapy
• •Prior therapy with tigecycline as an anti-cancer therapy or any use of the drug in the last month
• •Use of other investigational anti-leukemic therapy within 14 days of registration